Avalo Therapeutics (NASDAQ:AVTX) Upgraded at Wedbush

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by stock analysts at Wedbush to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

A number of other analysts have also recently issued reports on AVTX. HC Wainwright started coverage on Avalo Therapeutics in a report on Thursday, October 24th. They set a “neutral” rating on the stock. BTIG Research started coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective on the stock.

Avalo Therapeutics Price Performance

Shares of AVTX opened at $8.44 on Thursday. The stock’s 50-day simple moving average is $7.82 and its 200 day simple moving average is $9.40. Avalo Therapeutics has a 52-week low of $4.20 and a 52-week high of $34.46.

Hedge Funds Weigh In On Avalo Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after acquiring an additional 3,754 shares during the last quarter. Marshall Wace LLP bought a new position in Avalo Therapeutics in the 4th quarter worth about $114,000. Walleye Capital LLC bought a new position in Avalo Therapeutics in the 4th quarter worth about $145,000. Northern Trust Corp bought a new position in Avalo Therapeutics in the 4th quarter worth about $168,000. Finally, Bank of Montreal Can bought a new position in Avalo Therapeutics in the 4th quarter worth about $446,000. 87.06% of the stock is currently owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.